New drug aims to calm inflammation in kidney disease patients

NCT ID NCT06362759

Completed Disease control Sponsor: Tourmaline Bio, Inc., a Novartis Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times

Summary

This study tested a drug called TOUR006 in 143 adults with chronic kidney disease and high levels of a protein linked to inflammation (hs-CRP). The goal was to see if monthly or quarterly shots could safely lower inflammation. The study is complete, and results will show if the drug helps control disease-related inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome Hirschsprung disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

C-REACTIVE PROTEIN CHRONIC KIDNEY DISEASES CHRONIC KIDNEY INSUFFICIENCY CHRONIC RENAL DISEASES CHRONIC RENAL INSUFFICIENCY HIGH SENSITIVITY C-REACTIVE PROTEIN HS-CRP HSCRP KIDNEY INSUFFICIENCY, CHRONIC

Contacts and locations

Locations

Site - 0101

Birmingham, Alabama, 35209, United States
Site - 0102

Fort Mill, South Carolina, 29707, United States
Site - 0103

Greenville, South Carolina, 29607, United States
Site - 0104

Phoenix, Arizona, 85018, United States
Site - 0105

Houston, Texas, 77043, United States
Site - 0106

Chicago, Illinois, 60655, United States
Site - 0107

San Antonio, Texas, 78212, United States
Site - 0108

Knoxville, Tennessee, 37923, United States
Site - 0109

Manassas, Virginia, 20110, United States
Site - 0110

Charlotte, North Carolina, 28208, United States
Site - 0111

Lampasas, Texas, 76550, United States
Site - 0112

Valencia, California, 91355, United States
Site - 0113

Greenacres City, Florida, 334667, United States
Site - 0114

Council Bluffs, Iowa, 51501, United States
Site - 0115

Morton, Illinois, 61550, United States
Site - 0117

Fargo, North Dakota, 58104, United States
Site - 0119

Port Orange, Florida, 32127, United States
Site - 0120

Cincinnati, Ohio, 45219, United States
Site - 0122

Savannah, Georgia, 31406, United States
Site - 0123

Las Vegas, Nevada, 89121, United States
Site - 0125

San Dimas, California, 91773, United States
Site - 0126

Providence, Rhode Island, 02818, United States
Site - 0127

Marion, Ohio, 43302, United States
Site - 0128

Valencia, California, 91355, United States
Site - 0129

Metairie, Louisiana, 70006, United States
Site - 0130

Middletown, New York, 10940, United States
Site - 0132

Bethlehem, Pennsylvania, 18017, United States
Site - 0134

Kenosha, Wisconsin, 53144, United States
Site - 0135

Huntsville, Alabama, 35763, United States
Site - 0136

Stamford, Connecticut, 06905, United States
Site - 0141

San Antonio, Texas, 78255, United States
Site - 0144

Plantation, Florida, 33317, United States
Site - 0145

Huntsville, Alabama, 35805, United States
Site - 0147

Morgantown, West Virginia, 26505, United States
Site - 0148

Greenville, Texas, 75402, United States
Site - 0149

Pembroke Pines, Florida, 33024, United States
Site - 0150

McKinney, Texas, 75069, United States
Site - 0151

Tampa, Florida, 33634, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.